Core Points - Baicheng Pharmaceutical announced the resignation of its director and board secretary, Cheng Dandan, due to personal reasons, effective immediately upon delivery of the resignation report [2] - The company appointed Chen Shufeng as the new board secretary, with his term lasting until the end of the current board's tenure [2] - The board also approved the nomination of Chen Shufeng as a non-independent director candidate [2]

Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]

Core Insights - Baicheng Pharmaceutical (301096) has entered into an exclusive collaboration with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. for the innovative drug BIOS-0629 in the Greater China region, which includes mainland China and Hong Kong, Macau, and Taiwan [2] - The collaboration agreement will become effective upon approval by the company's shareholders [2] - Baicheng Pharmaceutical will be responsible for the research and development, clinical trials, and registration of the product, while Zhongshen Innovative will handle the R&D transformation, production, sales, and market expansion in the Greater China region [2] - Following the signing of the contract, Zhongshen Innovative will pay milestone payments of 300 million yuan based on R&D milestones [2] - After the product is launched in the Greater China region, Baicheng Pharmaceutical will receive a 10% commission on sales revenue [2]

Core Viewpoint - The company has entered into an exclusive collaboration with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for the innovative drug BIOS-0629 in the Greater China region, which includes mainland China and Hong Kong, Macau, and Taiwan [1] Group 1 - The collaboration agreement includes a milestone payment of 300 million yuan upon reaching specific research and development milestones [1] - The agreement will take effect after approval from the company's shareholders' meeting [1] - The company will receive a 10% commission on sales revenue once the product is launched in the Greater China region [1]

Core Viewpoint - The company has entered into an exclusive collaboration with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for the innovative drug BIOS-0629 in the Greater China region, aiming to accelerate the transition from laboratory results to clinical applications [1] Group 1: Collaboration Details - The company and Zhongshen Innovation have signed a Technical Development Cooperation Agreement and a supplementary agreement for the BIOS-0629 project [1] - The project is currently in the PCC stage and targets solid tumors as its indication [1] - The company will handle research, clinical trials, and registration applications, while Zhongshen Innovation will manage R&D transformation, post-market production, sales, and market expansion in the Greater China region [1] Group 2: Financial Aspects - Following the signing of the contract, Zhongshen Innovation will pay a milestone fee of 300 million yuan based on R&D milestones [1] - Upon the product's launch in the Greater China region, the company will receive a 10% commission on sales revenue [1] Group 3: Strategic Goals - The collaboration aims to leverage both parties' resources and technological advantages in innovative drug development to enhance collaborative innovation [1] - The partnership is expected to expedite the transition of the BIOS-0629 project from laboratory achievements to clinical applications, promoting innovative outcomes [1]

Core Viewpoint - The company has entered into an exclusive collaboration agreement with Zhongshen Innovation for the development of the innovative drug BIOS-0629 in the Greater China region, which includes mainland China and Hong Kong, Macau, and Taiwan [1] Group 1 - The collaboration includes a technical development cooperation agreement and a supplementary agreement [1] - Zhongshen Innovation will pay milestone payments of 300 million yuan based on research and development milestones [1] - Upon the product's launch in the Greater China region, the company will receive a 10% commission on sales revenue [1]

关于BIOS-0629项目签署《技术开发合作协议》 暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：301096 证券简称：百诚医药 公告编号：2025-063 杭州百诚医药科技股份有限公司 一、关联交易概述 杭州百诚医药科技股份有限公司（以下简称"公司"）与浙江众神创新医药科技 有限公司（以下简称"众神创新"）就 1 类创新药 BIOS-0629 项目达成大中华地区（大 陆及港澳台地区）独家授权合作并签署了《技术开发合作协议》及补充协议，合作协 议自公司股东大会审议通过后生效。 众神创新的法定代表人和高级管理人员冯恩光先生为公司原副总经理，其于 2025 年 2 月 7 日不再担任公司该职务并于 6 月离职。根据《深圳证券交易所创业板股票上 市规则》（以下简称"《上市规则》"），过去十二个月内担任公司高级管理人员的 人员为上市公司关联自然人，因冯恩光先生目前在众神创新担任高级管理人员，众神 创新为公司的关联法人。因此公司与众神创新的本次交易构成关联交易。 本次关联交易经公司第四届董事会 2025 年第一次独立董事专门会议审议通过， ...

证券代码：301096 证券简称：百诚医药 公告编号：2025-062 杭州百诚医药科技股份有限公司 关于董事、高级管理人员变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事、高级管理人员辞职情况 陈树峰先生熟悉履职相关的法律法规、具备与岗位要求相适应的职业操守及 履职能力。陈树峰先生已取得证券交易所颁发的《董事会秘书资格证书》，其任 职资格符合《深圳证券交易所创业板股票上市规则》等相关法律、法规的规定， 不存在不得担任董事会秘书的情形。 董事会秘书陈树峰先生联系方式如下： 电话：0571-87923909 传真：0571-87923909 电子邮箱：stock@hzbio-s.com 杭州百诚医药科技股份有限公司（以下简称"公司"）董事会于近日收到公 司董事、董事会秘书兼任财务总监程丹丹女士递交的书面辞任报告。程丹丹女士 因个人原因，申请辞去公司董事、董事会秘书职务，辞任报告自送达董事会之日 起生效，辞任后仍然担任公司财务总监职位。 程丹丹女士原定任期为 2025 年 2 月 7 日至 2028 年 2 月 6 日。截至本公告披 露日，程丹 ...

| 修订前 | | 修订后 | | --- | --- | --- | | 全文 | 监事、监事会 | 全文 删除 | | 全文 | 股东大会 | 全文 股东会 | | 第一条 | | 第一条 | | 为维护杭州百诚医药科技股份有限公 | | 为维护杭州百诚医药科技股份有限公 | | 司（以下简称"公司"）、股东和债权 | | 司（以下简称"公司"）、股东、职工 | | 人的合法权益，规范公司的组织和行 | | 和债权人的合法权益，规范公司的组织 | | 为，根据《中华人民共和国公司法》（以 | | 和行为，根据《中华人民共和国公司法》 | | 下简称《公司法》）、《中华人民共和 | | （以下简称《公司法》）、《中华人民 | | 国证券法》（以下简称《证券法》）和 | | 共和国证券法》（以下简称《证券法》） | | 其他有关国家法律、法规及规范性文件 | | 和其他有关国家法律、法规及规范性文 | | 的规定，制订本章程。 | | 件的规定，制定本章程。 | | | | 第八条 | | 第八条 | | 代表公司执行公司事务的董事为公司 | | 董事长为公司的法定代表人。 | | 的法定代表人，代表公司执行 ...

一、召开会议的基本情况 1、股东大会届次：2025 年第三次临时股东大会 证券代码：301096 证券简称：百诚医药 公告编号：2025-064 杭州百诚医药科技股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 4、会议时间： （1）现场会议时间：2025 年 12 月 08 日 14:30:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 08 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投 票的具体时间为 2025 年 12 月 08 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 12 月 02 日 7、出席对象： 2、股东大会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等法律 ...